Profile of Silodosin European Urology Supplements Francesco Montorsi  European Urology Supplements  Volume 9, Issue 4, Pages 491-495 (July 2010) DOI: 10.1016/j.eursup.2010.04.001 Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 1 Percentage of patients with reduction of at least one episode of nocturia (placebo=148; silodosin=308; tamsulosin=308). * p<0.05 versus placebo. European Urology Supplements 2010 9, 491-495DOI: (10.1016/j.eursup.2010.04.001) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 2 Percentage of patients with simultaneous improvement in incomplete emptying, frequency, and nocturia (patient population and subgroup with two or more episodes of nocturia). § p=0.02 versus placebo; p=0.03 versus tamsulosin. # p=0.04 versus placebo; p=0.03 versus tamsulosin. European Urology Supplements 2010 9, 491-495DOI: (10.1016/j.eursup.2010.04.001) Copyright © 2010 European Association of Urology Terms and Conditions